Microbiome Connect: ASIA 2023

Microbiome Connect: Where innovation meets industry

Uniting microbiome industry leaders in APAC to facilitate the development of optimised microbial therapeutics for clinical and commercial success

REGISTER NOW
Seoul, Republic of Korea
17-18 May, 2023

WELCOME TO MICROBIOME CONNECT

With APAC set to experience transformative growth, the need to build meaningful connections with microbiome biotechs, pharma voices, government officials, and investment bodies has never been stronger.

For developers of microbiome-based therapeutics, Microbiome Connect: Asia is a unique opportunity to advance your company along its commercialisation journey.

Following our flagship US and EU events, this forum is dedicated to accelerating pipeline development in APAC by showcasing updates from leading biotechs, addressing regional regulatory issues, and promoting collaboration between industry, academia, and service providers.

Join us in the hub of Asian microbiome research to adopt effective manufacturing strategies to achieve commercial scale, build collaborative relationships with regulatory bodies, and address current challenges associated with GMP production in Korea and beyond.

AUDIENCE BREAKDOWN

45%
Biotechs
15%
Pharma & Investors
25%
Academia
25%
Service Providers

Biotechs

Pharma & Investors

Academia

Service Providers

200+
Attendees in 2022
50+
Leading Top Speakers at past event
10+
Hours of Dedicated Networking

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

TICKET PRICE WILL INCREASE IN:

Wednesday, January 18, 2023 to Friday, April 28, 2023
Service Provider
$4165
including consultants, equipment manufacturers, platform technology and service provider companies
Access to 2 Conference Days
Networking Opportunities
Saturday, April 1, 2023 to Friday, April 28, 2023
Academics
$895
Researchers working solely at an Academic Institute or Hospital
Access to 2 Conference Days
Networking Opportunities
Saturday, April 1, 2023 to Friday, April 28, 2023
Biotech, Pharma & Investors
$2,025
Biotech representatives must have a publicly available active pipeline
Access to 2 Conference Days
Networking Opportunities
Preparing registration...

MICROBIOME CONNECT NETWORK

Past attendees, reflective of 2022. 

EVENT SCHEDULE

Download your copy of the BRAND NEW Microbiome Connect: Asia agenda - discover the full line up of industry leaders joining us in Seoul to share their insights.
Address your key challenges within both drug development and manufacturing by analysing a range of case-study presentations and panel discussions that provide an in-depth view of ongoing preclinical and clinical trials across immuno-oncology, neurology, cardiology, NASH and more.
To find out more about the series, check out the Microbiome Connect: USA and Microbiome Connect: Europe to discover what you can expect in May 2023.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

EVENT SCHEDULE

PRE-CLINICAL PROGRAM COMPETITION

INFORMATION

Showcase your promising pre-clinical programs to a jury of industry leading experts within microbiome for your opportunity to secure a full proof-of concept study. The Microbiome Connect Pre-Clinical Program competition is an opportunity for any LBP companies based in APAC to make the most of their conference attendance.

Three programs will be shortlisted by our jury to give a 10-minute presentation at the conference. With one overall winner announced who will receive a free full PoC study sponsored by Bacthera.


Deadlines for application: April 14 2023
Candidates announced: May 1 2023
Presentations: May 17 2023
Winner Announced: May 18 2023

COMPETITION PRIZE

The winning program will receive a full Drug Substance & Drug Product Proof of Concept Study sponsored by Bacthera during 2023/2024, based on Bacthera standard technologies (DS+DP):

  • Including high-throughput screening
  • Fermentation, drying, filling and testing of
    - 1x 2x 10L batch
    - Including 1-2 months stability study

    SUBMIT NOW

    POSTER SUBMISSIONS

    Are you looking to showcase your recent work to the Microbiome community?

    Our dedicated poster session is the perfect way to get your research noticed, ideal for PhD students or Post-Doctoral researchers.

    Subject to successful registration, your presentation will be displayed in a dedicated poster area at the event. The poster presentation session time of taking place is to be confirmed.

    SUBMISSION DEADLINE: 7PM (KST) FRIDAY APRIL 14 2023

    Abstracts received after this time may not be accepted so please submit your abstract as soon as possible! Academics that submit a poster abstract before April 14 get a $100 discount!

    Posters should be one page PDF, sized A0 (841mm x 1189mm) in portrait orientation.

    If you have any questions please contact [email protected] 

    Click HERE to make your submission before APRIL 14.

    SPEAKER FACULTY

     

    Jisoo Pae, MD, Psychiatrist, MBA

    Chief Executive Officer
    Genome & Company

    Jisoo Pae, MD, Psychiatrist, MBA

    Chief Executive Officer
    Genome & Company

    Jisoo Pae, MD, Psychiatrist, MBA

    Chief Executive Officer
    Genome & Company
     

    Clay (Young Suk) Kim, M.A.

    Chief Executive Officer
    GI Biome

    Clay (Young Suk) Kim, M.A.

    Chief Executive Officer
    GI Biome

    Clay (Young Suk) Kim, M.A.

    Chief Executive Officer
    GI Biome
     

    Jun Terauchi

    Chairperson of Steering Committee
    Japan Microbiome Consortium

    Jun Terauchi

    Chairperson of Steering Committee
    Japan Microbiome Consortium

    Jun Terauchi

    Chairperson of Steering Committee
    Japan Microbiome Consortium
     

    Taku Nakahara, Ph.D., MBA

    Co-Founder & CEO
    Metagen Therapeutics

    Taku Nakahara, Ph.D., MBA

    Co-Founder & CEO
    Metagen Therapeutics

    Taku Nakahara, Ph.D., MBA

    Co-Founder & CEO
    Metagen Therapeutics
     

    Sang Sun Yoon, Ph.D.

    Chief Executive Officer
    BioMe Inc.

    Sang Sun Yoon, Ph.D.

    Chief Executive Officer
    BioMe Inc.

    Sang Sun Yoon, Ph.D.

    Chief Executive Officer
    BioMe Inc.
     

    Kumar Sankaran

    Chief Executive Officer
    Leucine Rich Bio

    Dr. Song, Managing Director of LISCure, worked as a postdoc and instructor at Tulane University, School of Medicine, researching liver cancer and nonalcoholic steatohepatitis. He led the research and development of drugs for NASH and autoimmune diseases in the clinical stage by conducting research on the mechanism and efficacy of candidate substances and preclinical experiments at LISCure. He plays an important role in LISCure’s lab as well as global partnerships with Mayo Clinic and Scripps Labs.

    Kumar Sankaran

    Chief Executive Officer
    Leucine Rich Bio

    Kumar Sankaran

    Chief Executive Officer
    Leucine Rich Bio

    Dr. Song, Managing Director of LISCure, worked as a postdoc and instructor at Tulane University, School of Medicine, researching liver cancer and nonalcoholic steatohepatitis. He led the research and development of drugs for NASH and autoimmune diseases in the clinical stage by conducting research on the mechanism and efficacy of candidate substances and preclinical experiments at LISCure. He plays an important role in LISCure’s lab as well as global partnerships with Mayo Clinic and Scripps Labs.

     

    Wayne Finlayson, Ph.D.

    Chief Executive Officer
    Servatus

    Wayne Finlayson, Ph.D.

    Chief Executive Officer
    Servatus

    Wayne Finlayson, Ph.D.

    Chief Executive Officer
    Servatus
     

    Jongmin Paek

    Chief Manufacturing Officer
    Genome & Company

    Jongmin Paek

    Chief Manufacturing Officer
    Genome & Company

    Jongmin Paek

    Chief Manufacturing Officer
    Genome & Company
     

    Mirjana Rapaic

    Head of Regulatory Affairs
    BiomeBank

    Mirjana Rapaic

    Head of Regulatory Affairs
    BiomeBank

    Mirjana Rapaic

    Head of Regulatory Affairs
    BiomeBank
     

    Renato Lemgruber

    Senior Research Scientist
    Servatus

    Bachelor's Degree in Biological Sciences (Federal University of Parana, Brazil, 2009).

    Master of Science in Genetics, Conservation and Evolutionary Biology (National Institute of Amazonian Research, Brazil, 2012).

    PhD in Biotechnology (Systems and Synthetic Biology) (Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Australia, 2019).

    Member of The Higher Education Academy (HEA) as an Associate Fellow (Since March 2019)

    Renato Lemgruber

    Senior Research Scientist
    Servatus

    Renato Lemgruber

    Senior Research Scientist
    Servatus

    Bachelor's Degree in Biological Sciences (Federal University of Parana, Brazil, 2009).

    Master of Science in Genetics, Conservation and Evolutionary Biology (National Institute of Amazonian Research, Brazil, 2012).

    PhD in Biotechnology (Systems and Synthetic Biology) (Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Australia, 2019).

    Member of The Higher Education Academy (HEA) as an Associate Fellow (Since March 2019)

     

    Kyoungsub Song Ph.D.

    Chief Technology Officer
    LISCure Biosciences

    Kyoungsub Song has more than 15 years experience in the field of liver disease including NASH, cirrhosis, and cancers. He worked as a postdoc and instructor at Tulane University, School of Medicine. He joined LISCure Bioscience in 2020 and now serves as CTO. He led the research and development drugs for NASH in the clinical stage by conducting research on the mechanism and efficacy of candidate substances and preclinical experiments at LISCure. He was actively involved in LISCure’s global partnerships with Mayo Clinic and Scripps research.

    Kyoungsub Song Ph.D.

    Chief Technology Officer
    LISCure Biosciences

    Kyoungsub Song Ph.D.

    Chief Technology Officer
    LISCure Biosciences

    Kyoungsub Song has more than 15 years experience in the field of liver disease including NASH, cirrhosis, and cancers. He worked as a postdoc and instructor at Tulane University, School of Medicine. He joined LISCure Bioscience in 2020 and now serves as CTO. He led the research and development drugs for NASH in the clinical stage by conducting research on the mechanism and efficacy of candidate substances and preclinical experiments at LISCure. He was actively involved in LISCure’s global partnerships with Mayo Clinic and Scripps research.

     

    Heenam Stanley Kim, Ph.D.

    Professor
    Korea University

    Heenam Stanley Kim, Ph.D.

    Professor
    Korea University

    Heenam Stanley Kim, Ph.D.

    Professor
    Korea University
     

    Sin-Hyeog Im, Ph.D.

    Chief Executive Officer
    ImmunoBiome Inc.

    Sin-Hyeog Im, Ph.D.

    Chief Executive Officer
    ImmunoBiome Inc.

    Sin-Hyeog Im, Ph.D.

    Chief Executive Officer
    ImmunoBiome Inc.
     

    GwangPyo Ko, Ph.D.

    Founder & CEO
    KoBioLabs

    GwangPyo Ko, Ph.D.

    Founder & CEO
    KoBioLabs

    GwangPyo Ko, Ph.D.

    Founder & CEO
    KoBioLabs
     

    Sarah Haylock-Jacobs

    Head of Clinical Development
    BiomeBank

    Sarah is a PhD scientist with over 5 years experience designing and coordinating clinical trials in North America and Australia.

    She has experience with FDA and TGA governed clinical trials and co-ordinating hospital sites on large multicentre studies.

    Sarah Haylock-Jacobs

    Head of Clinical Development
    BiomeBank

    Sarah Haylock-Jacobs

    Head of Clinical Development
    BiomeBank

    Sarah is a PhD scientist with over 5 years experience designing and coordinating clinical trials in North America and Australia.

    She has experience with FDA and TGA governed clinical trials and co-ordinating hospital sites on large multicentre studies.

     

    Aaron Cowley, Ph.D., MBA

    Chief Scientific Officer
    Arranta Bio

    Aaron Cowley, Ph.D., MBA

    Chief Scientific Officer
    Arranta Bio

    Aaron Cowley, Ph.D., MBA

    Chief Scientific Officer
    Arranta Bio
     

    Byoung-Chan Kim

    Chief Executive Officer
    HealthBiome Inc

    Dr Byoung-Chan Kim received his B.S, M.S, and Ph.D. from Yonsei University (Department of Biotechnology) and is currently serving as Chief Executive Officer of HealthBiome Inc. His research interests include: isolation, taxonomic classification & fermentation of strict anaerobic bacteria. Dr Kim’s past roles include Professor of Microbiology at UMass, USA, and Senior/Principal Investigator at the Korea Research Institute of Bioscience & Biotechnology (KRIBB). 

    Byoung-Chan Kim

    Chief Executive Officer
    HealthBiome Inc

    Byoung-Chan Kim

    Chief Executive Officer
    HealthBiome Inc

    Dr Byoung-Chan Kim received his B.S, M.S, and Ph.D. from Yonsei University (Department of Biotechnology) and is currently serving as Chief Executive Officer of HealthBiome Inc. His research interests include: isolation, taxonomic classification & fermentation of strict anaerobic bacteria. Dr Kim’s past roles include Professor of Microbiology at UMass, USA, and Senior/Principal Investigator at the Korea Research Institute of Bioscience & Biotechnology (KRIBB). 

    OUR PROUD SPONSORS

    Headline Partner

    Platinum Partner

    Gold Partner

    Silver Partner

    Event Partner

    Media & press partners

    PARTNER WITH US

    Sponsorship

    Let us create a bespoke package based on your specific objectives, and showcase your brand to the microbiome community.

    Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.

    Contact [email protected]

    Media & Press

    Connecting the microbiome community is essential for progress in the field.

    We'd love to hear from you and how we can support one another to connect leaders in the industry and share important insights.

    Contact [email protected]

    Venue

    Hotel Naru Seoul - MGallery 8 Mapo-daero, Mapo-gu, Seoul, 04176 - Republic of Korea

    Microbiome Connect invites you to join us at Hotel Naru Seoul MGallery Ambassador on the 17th-18th May 2023.

    Book your hotel room here.

    About Kisaco Research

    Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

    Meet industry peers that will help build a career-changing network for life.

    Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

    Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

    Invest both in your company growth and your own personal development by signing up to one of our events and get started.

    Contact Us

    Other events you might be interested in:

    AMR Connect 2023

    Microbiome Connect: USA 2023

    Microbiome Connect: Europe 2023